Appraising Drugs Based on Cost-effectiveness and Severity of Disease in Norwegian Drug Coverage Decisions.

Tranvåg, Eirik Joakim; Haaland, Øystein Ariansen; Robberstad, Bjarne; Norheim, Ole Frithjof

Tranvåg, Eirik Joakim; Haaland, Øystein Ariansen; Robberstad, Bjarne; Norheim, Ole Frithjof.

Afiliación

Tranvåg EJ; Bergen Centre for Ethics and Priority Setting, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
Haaland ØA; Centre for Cancer Biomarkers, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
Robberstad B; Bergen Centre for Ethics and Priority Setting, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
Norheim OF; Research Group in Health Economics, Leadership, and Translational Ethics Research, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.

JAMA Netw Open ; 5(6): e2219503, 2022 06 01.

Article en En | MEDLINE | ID: mdl-35767256

Asunto(s)

Antineoplásicos; Costos de los Medicamentos; Análisis Costo-Beneficio; Estudios Transversales; Humanos; Índice de Severidad de la Enfermedad

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Costos de los Medicamentos / Antineoplásicos Tipo de estudio: Health_economic_evaluation / Health_technology_assessment / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: JAMA Netw Open Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google